Marksans Pharma Limited (MARKSANS:NSE) Annual Income Statement (INR)
MARKSANS:NSE Quarterly Financials (INR)
Frequently Asked Questions About Marksans Pharma Limited (MARKSANS:NSE) Stock
Marksans Pharma Limited's (MARKSANS:NSE) last reported annual revenue was INR 18.52 Billion.
Marksans Pharma Limited's (MARKSANS:NSE) annual revenue growth rate based on the revenue reported in the past 5 years is : 15.20%
Marksans Pharma Limited's(MARKSANS:NSE) is profitable as of its last reported annual financials.
The net profit margin for Marksans Pharma Limited's(MARKSANS:NSE) from its laster reported year is 14.38%
The return on equity (ROE) for Marksans Pharma Limited's(MARKSANS:NSE) from its last reported annual financials is : 18.83%
The return on assets (ROA) for Marksans Pharma Limited's(MARKSANS:NSE) from its last reported annual financials is : 10.81%
The return on invested capital (ROIC) for Marksans Pharma Limited's(MARKSANS:NSE) from its last reported annual financials is : 14.22%
The Debt to Equity ratio for Marksans Pharma Limited's(MARKSANS:NSE) from its last reported annual financials is : 0.00%
The dividend yield for Marksans Pharma Limited's(MARKSANS:NSE) from its laster reported year is 0.33%
Marksans Pharma Limited's(MARKSANS:NSE) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced on cashflow basis
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
What not to like
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MARKSANS:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
